CSET submitted the following comment in response to a Request for Information (RFI) from the National Science Foundation (NSF) about the development of the newly established Technology, Innovation, and Partnerships (TIP) Directorate, in accordance with the CHIPS and Science Act of 2022.

Vaccines keep the U.S. public healthy while safeguarding economic stability and biosecurity. This report assesses the domestic vaccine manufacturing landscape and identifies two major vulnerabilities: a reliance on foreign manufacturers and a lack of manufacturing redundancy. Maintaining a resilient vaccine supply will require the U.S. government to take steps to protect the existing supply, identify and monitor manufacturing vulnerabilities, and create a stronger domestic production base.

Pandemic threats are increasing as globalization, urbanization, and encroachment on animal habitats cause infectious outbreaks to become more frequent and severe. It is imperative that the United States build a pipeline of medical countermeasure development, beginning with basic scientific research and culminating in approved therapies. This report assesses preparedness for families of viral pathogens of pandemic potential and offers recommendations for steps the U.S. government can take to prepare for future pandemics.

CSET Research Analyst Dahlia Peterson testified before the U.S.-China Economic and Security Review Commission at a hearing on "China’s Challenges and Capabilities in Educating and Training the Next Generation Workforce."

U.S. policymakers are increasingly concerned about the national security implications of U.S. investments in China, and some are considering a new regime for reviewing outbound investment security. The authors identify the main U.S. investors active in the Chinese artificial intelligence market and the set of AI companies in China that have benefitted from U.S. capital. They also recommend next steps for U.S. policymakers to better address the concerns over capital flowing into the Chinese AI ecosystem.

CSET Non-Resident Senior Fellow Kevin Wolf testified before the Senate Banking Committee on U.S. export control policy and opportunities.

CSET's Dr. Caroline Schuerger, Dr. Steph Batalis, and Vikram Venkatram submitted this comment with recommendations for the National Biotechnology and Biomanufacturing Initiative.

CSET Non-Resident Senior Fellow Kevin Wolf testified before the House Foreign Affairs Oversight and Accountability Subcommittee regarding U.S. export control policy and his recommendations going forward.

CSET Non-Resident Senior Fellow Kevin Wolf testified before the United Kingdom Parliament on export controls and Russia.

U.S. federal policymakers have recently gained the authority to block government agencies and private organizations from using foreign technologies that pose national security risks. But securing U.S. networks will require them to wield those powers effectively and better coordinate supply chain security efforts across all levels of government. The authors provide an overview of federal- and state-level procurement bans and recommend ways to build stronger defense against foreign technology threats.